Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Perceptive Advisors

Investor type Hedge Fund

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 215
Average round size
info
The average size of a deal this fund participated in
$90M
Portfolio companies 168
Rounds per year 9.35
Lead investments 50
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 92
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

The venture was found in North America in United States. The main department of described VC is located in the New York.

We also calculated 3 valuable employees in our database.

The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. This Perceptive Advisors works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The typical startup value when the investment from Perceptive Advisors is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The increased amount of exits for fund were in 2018.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, BridgeBio, Alector. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Genetics, Biopharma.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Perceptive Advisors, startups are often financed by Third Rock Ventures, F-Prime Capital, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are ArrowMark Partners, RTW Investments LLC, Viking Global Investors. In the next rounds fund is usually obtained by OrbiMed, Pontifax, Warburg Pincus.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Perceptive Advisors:
Typical Co-investors
Perceptive Advisors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Perceptive Advisors:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Solid Biosciences

Biotechnology
Genetics
Health Care
Medical
$75M30 Sep 2022 Marlborough, Massachusetts, United States

SpringWorks Therapeutics

Biopharma
Biotechnology
Therapeutics
$225M07 Sep 2022 Stamford, Connecticut, United States

InSightec

Biotechnology
Health Care
Manufacturing
Medical Device
Therapeutics
$100M01 Sep 2022 Israel, North District, Israel

MeiraGTx

Biotechnology
Health Care
Therapeutics
$75M03 Aug 2022 New York, New York, United States

Cerebral Therapeutics

Health Care
Pharmaceutical
Therapeutics
$40M28 Jun 2022 Aurora, Colorado, United States

Surf Bio

Biotechnology
Pharmaceutical
$16M12 Apr 2022 Palo Alto, California, United States

Lyra Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
Wellness
$100M08 Apr 2022 Massachusetts, United States

Neuron23

Health Care
Medical
$100M30 Mar 2022 San Francisco, California, United States

DNAnexus

Bioinformatics
Biotechnology
Cloud Computing
Genetics
Medical
$200M08 Mar 2022 Mountain View, California, United States
News
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market

– Emulate, Inc. announced the close of an $82m Series E financing round.
– The round was led by Northpond Ventures with additional participation from Perceptive Advisors.
– With this investment, Emulate has raised nearly $225m to date.
– Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.
– Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Perceptive Advisors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: